Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boya Immunoglobulin Linked To Patient Deaths

This article was originally published in PharmAsia News

Executive Summary

Following investigation of the six deaths attributed to lethal immunoglobulin from Jiangxi Boya Bio-Pharmaceutical, China's State FDA announced that the National Institute for the Control of Pharmaceutical and Biological Products has confirmed that the samples identified were directly linked to the patients who died. According to results of tests conducted, the drugs in question are confined to batch 20070514, and relevant authorities are examining the exact cause of the problem. The batch has been traced and is under effective control nationwide. SFDA revealed that last year, 547,000 adverse drug reports were received, 48.1 percent more than 2006. The rising incidence warrants greater attention for the welfare of affected consumers. (Click here for more - Chinese Language)

You may also be interested in...

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts